UK Authorization for Aflibercept - Takeaways - MDSpire

UK Authorization for Aflibercept

MHRA clears Eylea for macular edema following retinal vein occlusion

Share

1

The UK MHRA has authorized aflibercept 8 mg for treating visual impairment due to retinal vein occlusion.
2

This approval is based on the Phase III QUASAR trial, demonstrating non-inferior visual acuity gains compared to aflibercept 2 mg.
3

Patients receiving aflibercept 8 mg required fewer injections on average than those receiving the 2 mg formulation.
4

Over 60% of patients in the 8 mg group achieved treatment intervals of four months or longer by week 64.
5

The authorization aims to reduce injection burden while maintaining visual outcomes for patients with RVO.